Qadir Muhammad Imran, Rizvi Samana Zahra
Institute of Molecular Biology and Biotechnology, Bahauddin Zakariya University, Multan, Pakistan.
Crit Rev Eukaryot Gene Expr. 2017;27(4):355-361. doi: 10.1615/CritRevEukaryotGeneExpr.2017019539.
Hepatocellular carcinoma (HCC) is a worldwide disease. Because therapeutic measures are ineffective, HCC currently has a poor prognosis. The main causes of HCCs are alcoholism, hepatitis, and metabolic syndrome. Normally hygieinic studies revealed that there is lower survival rate of HCC. MicroRNAs (miRNAs) consist of short noncoding sequences of RNA (20 to 24 nucleotides), which posttranscriptionally regulate the expression of the protein coding genes. MicroRNAs have been proposed to be prospective therapeutic molecules and targets. For testing miRNA-based therapies, HCC is a remarkable model because it may be targeted by delivery of oligonucleotides. Current studies show a beginning for analyzing the therapeutic prospects of miRNAs or anti-miRNAs. Generally, antitumor activity of miRNAs has been observed.
肝细胞癌（HCC）是一种全球性疾病。由于治疗措施无效，目前HCC的预后较差。HCC的主要病因是酗酒、肝炎和代谢综合征。常规卫生学研究表明，HCC患者的生存率较低。微小RNA（miRNA）由短的非编码RNA序列（20至24个核苷酸）组成，它们在转录后调节蛋白质编码基因的表达。miRNA已被认为是有前景的治疗分子和靶点。对于测试基于miRNA的疗法，HCC是一个显著的模型，因为它可以通过寡核苷酸递送进行靶向治疗。目前的研究显示了分析miRNA或抗miRNA治疗前景的开端。一般来说，已经观察到miRNA的抗肿瘤活性。
